Renalytix Statistics
Total Valuation
Renalytix has a market cap or net worth of 35.47 million. The enterprise value is 33.96 million.
| Market Cap | 35.47M |
| Enterprise Value | 33.96M |
Important Dates
The next estimated earnings date is Monday, June 16, 2025.
| Earnings Date | Jun 16, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +39.71% |
| Shares Change (QoQ) | +62.92% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 202.79M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 12.26 |
| PB Ratio | -25.91 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -1.21 |
| EV / Sales | 10.97 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -1.26 |
Financial Position
The company has a current ratio of 2.43
| Current Ratio | 2.43 |
| Quick Ratio | 2.20 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.31 |
| Interest Coverage | -232.81 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -128.10% |
| Return on Invested Capital (ROIC) | -395.18% |
| Return on Capital Employed (ROCE) | -340.56% |
| Revenue Per Employee | 28,373 |
| Profits Per Employee | -276,029 |
| Employee Count | 102 |
| Asset Turnover | 0.25 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 0.23 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 45.70 |
| Average Volume (20 Days) | 10,867 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Renalytix had revenue of 2.89 million and -28.16 million in losses. Loss per share was -0.22.
| Revenue | 2.89M |
| Gross Profit | 568,000 |
| Operating Income | -23.28M |
| Pretax Income | -28.15M |
| Net Income | -28.16M |
| EBITDA | -23.17M |
| EBIT | -23.28M |
| Loss Per Share | -0.22 |
Balance Sheet
The company has 9.63 million in cash and 8.21 million in debt, giving a net cash position of 1.42 million.
| Cash & Cash Equivalents | 9.63M |
| Total Debt | 8.21M |
| Net Cash | 1.42M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | -1.37M |
| Book Value Per Share | -0.00 |
| Working Capital | 6.59M |
Cash Flow
In the last 12 months, operating cash flow was -26.86 million and capital expenditures -4,000, giving a free cash flow of -26.86 million.
| Operating Cash Flow | -26.86M |
| Capital Expenditures | -4,000 |
| Free Cash Flow | -26.86M |
| FCF Per Share | n/a |
Margins
| Gross Margin | 19.63% |
| Operating Margin | -804.46% |
| Pretax Margin | -972.81% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Renalytix does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -39.71% |
| Shareholder Yield | -39.71% |
| Earnings Yield | -79.37% |
| FCF Yield | -75.72% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Renalytix has an Altman Z-Score of -23.03. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -23.03 |
| Piotroski F-Score | n/a |